USFDA approves Pfizer’s Litfulo for adults and adolescents with severe alopecia areata
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
This request for withdrawal of the two dossiers was made after necessary consultations and receiving guidance from EMA
The product will be produced at the Eugia Pharma Specialities, Unit-I, Medchal, Malkajgiri District, Telangana, India
The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries
This product will be manufactured at Lupin's Pithampur facility in India
Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
The group now has 372 approvals and has so far filed over 442* ANDAs since the commencement of the filing process in FY 2003-04.
This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
Subscribe To Our Newsletter & Stay Updated